Curis Announces $7M Securities Purchase Agreement

Curis ( (CRIS) ) just unveiled an announcement.

On July 2, 2025, Curis, Inc. announced a securities purchase agreement with institutional investors to raise approximately $7 million through a combination of registered direct offerings and private placements. This financial move is expected to support the company’s operations into the first quarter of 2026, providing a cash runway to advance its research and development programs. The agreement includes the issuance of common stock and warrants, with the offerings anticipated to close by July 3, 2025, subject to customary conditions. The company has engaged Laidlaw & Company and JonesTrading Institutional Services as co-placement agents for the transaction.

The most recent analyst rating on (CRIS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Spark’s Take on CRIS Stock

According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.

Curis’ overall stock score reflects its significant financial challenges, including persistent losses and negative cash flows. Despite positive developments in clinical trials, ongoing profitability issues and a weak valuation heavily weigh down the score.

To see Spark’s full report on CRIS stock, click here.

More about Curis

Curis, Inc. operates in the biotechnology industry, focusing on the development of innovative therapeutics for the treatment of cancer. The company is particularly engaged in advancing its clinical programs for emavusertib, a potential first-in-class inhibitor of IRAK4, which is being evaluated in various cancer types including Non-Hodgkin Lymphoma and Acute Myeloid Leukemia.

Average Trading Volume: 92,332

Technical Sentiment Signal: Strong Sell

Current Market Cap: $22.49M

See more data about CRIS stock on TipRanks’ Stock Analysis page.